Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults

NCT07754045 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity & Overweight

Interventions

DRUG: LUM-201
DRUG: Placebo
DRUG: Semagludtide

Sponsor

Lumos Pharma